RxDoctor Payments Data

George Goodman, OD

Optometrist · Dallas, TXNPI 1790893394

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 32 payments — averaging $40.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$531
  • Kala Pharmaceuticals, Inc.$212
  • Bausch & Lomb Americas Inc.$208
  • Carl Zeiss Meditec, Inc.$134
  • Sun Pharmaceutical Industries Inc.$58
  • AbbVie$46
  • plus $112 from 3 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,301 in reported general payments places this provider in the 60th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$172,179
Medicare patients
547
Services billed
1,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost55$23,782
RestasisCyclosporine30$13,049
XiidraLifitegrast17$10,988
Latanoprost681$5,407
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat243$4,490
Prednisolone Acetate90$4,436
RhopressaNetarsudil Mesylate13$4,111
Brimonidine Tartrate293$2,224
Prednisolone Sodium Phosphate35$1,457
Dorzolamide Hcl44$950
MoxifloxacinMoxifloxacin Hcl38$919
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha35$424
Ketorolac Tromethamine13$304
Timolol Maleate25$221
Methylprednisolone14$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$46$13,04930 claims
Bausch & Lomb Americas Inc.Xiidra$208$10,98817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →